Northwest Bioth Cmn (NWBO): Price and Financial Metrics

Northwest Bioth Cmn (NWBO): $0.59

0.02 (-2.68%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add NWBO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#183 of 350

in industry

NWBO Price/Volume Stats

Current price $0.59 52-week high $1.09
Prev. close $0.61 52-week low $0.40
Day low $0.58 Volume 1,461,800
Day high $0.62 Avg. volume 1,923,189
50-day MA $0.67 Dividend yield N/A
200-day MA $0.66 Market Cap 701.45M

NWBO Stock Price Chart Interactive Chart >

NWBO POWR Grades

  • Growth is the dimension where NWBO ranks best; there it ranks ahead of 77.62% of US stocks.
  • NWBO's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • NWBO's current lowest rank is in the Quality metric (where it is better than 10.79% of US stocks).

NWBO Stock Summary

  • With a price/sales ratio of 370.96, NORTHWEST BIOTHERAPEUTICS INC has a higher such ratio than 98.83% of stocks in our set.
  • Over the past twelve months, NWBO has reported earnings growth of -206.67%, putting it ahead of merely 6.31% of US stocks in our set.
  • As for revenue growth, note that NWBO's revenue has grown 91.9% over the past 12 months; that beats the revenue growth of 95.13% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NORTHWEST BIOTHERAPEUTICS INC are FCEL, ASXC, LCTX, LGVN, and OMIC.
  • NWBO's SEC filings can be seen here. And to visit NORTHWEST BIOTHERAPEUTICS INC's official web site, go to www.nwbio.com.

NWBO Valuation Summary

  • In comparison to the median Healthcare stock, NWBO's price/sales ratio is 9140.48% higher, now standing at 388.1.
  • Over the past 243 months, NWBO's price/sales ratio has gone up 379.6.

Below are key valuation metrics over time for NWBO.

Stock Date P/S P/B P/E EV/EBIT
NWBO 2023-12-29 388.1 -12.4 -11.0 -12.6
NWBO 2023-12-27 398.7 -12.8 -11.3 -12.9
NWBO 2023-12-26 404.2 -12.9 -11.5 -13.1
NWBO 2023-12-22 415.3 -13.3 -11.8 -13.4
NWBO 2023-12-21 451.2 -14.4 -12.8 -14.6
NWBO 2023-12-20 398.7 -12.8 -11.3 -12.9

NWBO Growth Metrics

    The 2 year cash and equivalents growth rate now stands at 811.39%.
  • The 5 year net income to common stockholders growth rate now stands at 103.65%.
  • Its 4 year price growth rate is now at 137.5%.
Over the past 15 months, NWBO's revenue has gone down $288,000.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.086 -55.172 56.586
2022-06-30 1.23 -46.067 134.957
2022-03-31 1.169 -38.018 169.035
2021-12-31 1.005 -38.299 179.126
2021-09-30 1.508 -37.256 -234.493
2021-06-30 1.374 -38.265 -474.108

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
  • NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
  • EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.

The table below shows NWBO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 1 1.610
2021-03-31 0.036 1 2.337
2020-12-31 0.061 1 3.470
2020-09-30 0.112 1 3.430
2020-06-30 0.190 1 1.815
2020-03-31 0.245 1 -0.306

Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about NORTHWEST BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Yahoo | December 21, 2023

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Yahoo | November 22, 2023

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about its progress toward submission of a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Yahoo | October 13, 2023

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).

Yahoo | September 12, 2023

Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that it plans to submit a Marketing Authorization Application (MAA) in the U.K., to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA), for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Yahoo | August 29, 2023

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo -9.20%
3-mo -34.44%
6-mo 18.36%
1-year -16.31%
3-year -63.13%
5-year 140.33%
YTD -15.83%
2023 -10.64%
2022 12.07%
2021 -54.10%
2020 609.63%
2019 4.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!